src-1 Antibody

What is SRC-1 and why is it important in research?

SRC-1 (steroid receptor coactivator-1) is a member of a gene family that functions in the full transcriptional activation of the steroid hormone receptor superfamily and contains intrinsic histone acetyltransferase activity. It has a molecular weight of approximately 160 kDa and contains a basic helix-loop-helix (bHLH)-PAS domain . SRC-1 is primarily located in the nucleus, where it interacts with transcription factors to enhance the transcription of target genes. Its nuclear localization is vital because it allows for precise regulation of gene expression in response to hormonal signals, thereby influencing various physiological processes such as metabolism, development, and reproduction . Additionally, SRC-1 undergoes post-translational modifications, including phosphorylation, which can modulate its activity and interactions with other proteins, further emphasizing its importance in cellular signaling pathways .

What are the common applications of SRC-1 antibody in research?

The SRC-1 antibody has been successfully employed in multiple experimental applications, most prominently:

• Western blotting: SRC-1 antibody (e.g., MA1-840) detects an ~165 kDa protein representing SRC-1 in cell extracts .

• Immunoprecipitation: For protein complex isolation and interaction studies .

• Immunofluorescence: To visualize cellular localization of SRC-1 protein .

• Immunohistochemistry: For detection of SRC-1 in tissue sections, particularly in brain tissue research where specific protocols involving paraformaldehyde fixation and citrate buffer antigen retrieval have been established .

Each application requires specific optimization of antibody concentration, incubation conditions, and detection methods to ensure specificity and reproducibility.

How should I prepare tissue samples for SRC-1 immunostaining?

For optimal SRC-1 immunostaining, particularly in brain tissues, follow this methodological approach:

• Anesthetize subjects and perform perfusion with 4% paraformaldehyde in PBS.

• Remove the tissue and post-fix in the same fixative for 16 hours at 4°C.

• Dehydrate samples through an ethanol series, clear in xylene, and embed in paraffin.

• Section tissues at approximately 7 μm thickness.

• For antigen retrieval, dewax and rehydrate sections, then boil for 10 minutes in 10 mM citrate buffer (pH 6.0).

• Block endogenous peroxidase activity using 0.3% H₂O₂ in methanol for 15 minutes.

• Reduce non-specific binding by pre-incubating with 500 μg/ml goat IgG and 5% bovine serum albumin in PBS for 60 minutes at room temperature.

• Incubate with SRC-1 antibody (typically at 1:400 dilution) overnight at 4°C.

• Wash in PBS containing 0.075% Brij 35, then incubate with HRP-conjugated secondary antibody.

• Visualize using 3,3′-diaminobenzidine (DAB) and counterstain as needed .

This protocol has been validated for brain tissue but can be adapted for other tissue types with appropriate controls.

What are the common cross-reactivity issues with SRC-1 antibodies?

When working with SRC-1 antibodies, researchers should be aware of potential cross-reactivity issues. For instance, the MA1-840 antibody, while specific for SRC-1, has been shown to detect an unidentified protein at ~30-40 kDa in addition to the expected ~165 kDa SRC-1 protein. Additionally, this antibody does not react with NIH-3T3 cells in Western blot applications . To ensure specificity:

• Always include appropriate positive and negative controls in your experiments.

• Consider species-specific variations: SRC-1 antibody clone 1135/H4 detects SRC-1 from mouse, rat, and human origins, but sensitivity may vary across species .

• Validate antibody specificity in your specific experimental system using knockdown or knockout controls when possible.

• Be aware of potential cross-reactivity with other SRC family members or proteins with similar epitopes.

How can I optimize SRC-1 antibody use for studying its role in breast cancer tamoxifen resistance?

Research has demonstrated that SRC is up-regulated in tamoxifen-resistant breast cancer cells and is associated with poor prognosis in tamoxifen-treated breast cancer . When investigating SRC-1's role in tamoxifen resistance mechanisms, consider these methodological approaches:

• Cellular models: Establish tamoxifen-resistant cell lines (e.g., T47DR) by exposing sensitive cells (e.g., T47D) to 1 μmol/L 4-Hydroxytamoxifen for at least 6 months. Verify resistance through viability assays and morphological analysis .

• Expression analysis workflow:

  • Compare SRC-1 expression between sensitive and resistant cells using both protein (Western blot) and mRNA (qRT-PCR) analyses

  • Validate findings using patient-derived xenografts or clinical samples

  • Correlate expression with clinical outcomes using public datasets (e.g., GSE9893, GSE31831)

• Functional validation:

  • Use siRNA or CRISPR to down-regulate SRC-1 in resistant cells

  • Assess the effect on tamoxifen sensitivity using proliferation and apoptosis assays

  • Investigate downstream mechanisms by examining SIRT1 expression levels, which have been shown to be regulated by SRC and contribute to tamoxifen resistance

What are the best approaches for studying SRC-1 in neurological development and function?

To investigate SRC-1's role in brain development and function, researchers have employed various techniques. Based on previous studies, the following comprehensive approach is recommended:

• Temporal and spatial expression analysis:

  • Perform immunohistochemistry on brain sections using validated SRC-1 antibodies

  • Compare expression across different developmental stages and brain regions

  • Combine with co-staining for cell-type specific markers (e.g., calbindin for Purkinje cells, synaptophysin for synaptic vesicles) to identify specific neuronal populations expressing SRC-1

• Functional characterization using knockout models:

  • Generate or obtain SRC-1 null mice to study phenotypic consequences

  • Assess behavior using standardized tests for motor function, learning, and memory

  • Examine neuroanatomical changes through histological analyses

• Molecular mechanism exploration:

  • Investigate SRC-1 interactions with nuclear receptors in specific neuronal populations

  • Analyze histone acetylation patterns in the presence and absence of SRC-1

  • Study the impact of SRC-1 on gene expression profiles in various brain regions

Previous studies have shown that SRC-1 null mice exhibit moderate motor dysfunction and delayed development of specific neuronal populations, highlighting the importance of this coactivator in brain function .

How can SRC-1 antibodies be used to investigate the relationship between SRC inhibitors and MCL-1 antagonists in leukemia research?

Recent research has identified important interactions between SRC inhibition and MCL-1 antagonism in acute myeloid leukemia (AML). To investigate this relationship using SRC-1 antibodies:

• Protein expression analysis:

  • Use Western blotting with SRC-1 antibodies to monitor expression levels in leukemia cell lines (e.g., U937, MV4-11, MOLM-13, OCI-AML3) following treatment with:
    a) MCL-1 antagonists alone (e.g., S63845, MIK665)
    b) Src inhibitors alone (e.g., SKI-606)
    c) Combination treatments

  • As shown in recent studies, MCL-1 antagonists like S63845 can sharply increase MCL-1 expression in AML cells, while co-administration with Src inhibitors blocks this effect

• Functional validation:

  • Perform ectopic expression of SRC-1 using expression vectors

  • Assess how altered SRC-1 levels affect cell viability, apoptosis (PARP and caspase-3 cleavage, γH2A.X formation, Annexin V staining), and drug responses

  • Research has demonstrated that cells ectopically expressing MCL-1 were protected from S63845/SKI-606-mediated cell death compared to empty-vector controls

• Signaling pathway analysis:

  • Use immunoprecipitation with SRC-1 antibodies to identify interaction partners

  • Investigate phosphorylation status of SRC-1 and related proteins

  • Examine how these interactions are affected by drug treatments

This approach can help elucidate the molecular mechanisms by which Src inhibitors prevent MCL-1 antagonist-induced MCL-1 up-regulation and enhance anti-leukemic activity.

What controls should be included when using SRC-1 antibodies for immunohistochemistry?

When performing immunohistochemistry with SRC-1 antibodies, proper controls are essential for reliable interpretation. Include the following controls:

• Positive tissue controls:

  • Tissues known to express SRC-1 (e.g., specific brain regions, hormone-responsive tissues)

  • Cell lines with confirmed SRC-1 expression (e.g., COS cells for MA1-840 antibody)

• Negative tissue controls:

  • Tissues or cells known not to express SRC-1

  • For MA1-840 antibody, NIH-3T3 cells have been documented as negative controls for Western blot

• Technical controls:

  • Primary antibody omission: Perform the entire staining protocol without the primary antibody

  • Isotype control: Use non-specific IgG of the same isotype (e.g., mouse IgG1 for SRC-1 Antibody 1135/H4)

  • Absorption control: Pre-incubate the antibody with the immunizing peptide before application

• Validation controls:

  • Comparison with mRNA expression by in situ hybridization

  • Correlation with results from other antibody clones or detection methods

  • Tissue from SRC-1 knockout models as definitive negative controls

Following this comprehensive control strategy will help ensure the specificity and reliability of your SRC-1 immunohistochemistry results.

Why might I detect multiple bands when using SRC-1 antibody in Western blot?

When performing Western blot with SRC-1 antibodies, researchers sometimes observe additional bands besides the expected ~165 kDa SRC-1 protein. This could be due to several factors:

• Known cross-reactivity: Some antibodies, like MA1-840, are documented to detect an unidentified protein at ~30-40 kDa in addition to SRC-1 . This is a known characteristic of the antibody rather than a technical issue.

• Post-translational modifications: SRC-1 undergoes various modifications, including phosphorylation , which can alter its molecular weight and result in multiple bands.

• Alternative splicing: SRC-1 has multiple isoforms, including SRC-1 (-Q), which may appear as distinct bands on a Western blot .

• Proteolytic degradation: Improper sample handling or insufficient protease inhibitors can lead to protein degradation, resulting in lower molecular weight fragments.

To troubleshoot and optimize:

• Use fresh samples with complete protease inhibitor cocktails

• Optimize lysis conditions and denaturing protocols

• Validate using positive and negative control cell lines

• Consider using phosphatase inhibitors if studying phosphorylated forms

• Verify your findings with different SRC-1 antibody clones

How can I optimize SRC-1 antibody dilution for different experimental applications?

Optimal antibody dilution varies by application type, detection method, and specific antibody clone. For SRC-1 antibodies:

To optimize:

• Perform a dilution series experiment for your specific tissue/cell type

• Include positive and negative controls at each dilution

• Evaluate signal-to-noise ratio, not just signal intensity

• Once optimized, maintain consistent conditions for reproducible results

• Consider lot-to-lot variations when using different antibody batches

What are the best methods to validate SRC-1 antibody specificity?

Validating antibody specificity is critical for reliable research. For SRC-1 antibodies, employ these validation methods:

• Genetic validation:

  • Use CRISPR/Cas9 or siRNA to generate SRC-1 knockout or knockdown samples

  • Compare antibody staining in wild-type versus knockout/knockdown samples

  • This is the gold standard for antibody validation

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide (for MA1-840, a synthetic peptide corresponding to residues 477-947 of human SRC-1)

  • The specific signal should be reduced or eliminated in Western blot or immunostaining

• Orthogonal validation:

  • Compare protein detection with mRNA expression levels

  • Use multiple antibodies targeting different epitopes of SRC-1

  • Correlate results with functional assays that manipulate SRC-1 expression

• Independent method validation:

  • Verify results using techniques like mass spectrometry

  • Use tagged SRC-1 constructs in overexpression studies

  • Compare with published data on SRC-1 expression patterns

These validation approaches will help ensure that your observations are due to specific detection of SRC-1 rather than non-specific binding or artifacts.

How can SRC-1 antibodies be applied in cancer research beyond breast cancer?

While SRC-1's role in breast cancer, particularly in tamoxifen resistance , is well-established, SRC-1 antibodies have valuable applications across multiple cancer types:

These applications highlight the versatility of SRC-1 antibodies in uncovering novel cancer biology and developing therapeutic strategies.

What are the emerging research areas where SRC-1 antibodies will be particularly valuable?

Several emerging research areas represent exciting opportunities for SRC-1 antibody applications:

• Single-cell analysis:

  • Use SRC-1 antibodies in single-cell Western blotting or mass cytometry (CyTOF)

  • Examine cell-to-cell heterogeneity in SRC-1 expression within tumors or tissues

  • Correlate with other signaling molecules at single-cell resolution

• Liquid biopsy development:

  • Investigate SRC-1 as a potential biomarker in circulating tumor cells

  • Develop sensitive detection methods using SRC-1 antibodies

  • Monitor therapy response through serial sampling

• Combination therapy mechanism studies:

  • Building on findings that SRC inhibition potentiates MCL-1 antagonist activity

  • Use SRC-1 antibodies to monitor dynamic changes during combination treatments

  • Identify predictive biomarkers for combination therapy response

• Neurodegenerative disease research:

  • Given SRC-1's role in brain development and function

  • Investigate potential connections to neurodegenerative conditions

  • Study interactions between SRC-1 and disease-associated proteins

These emerging areas highlight the continued importance of high-quality, validated SRC-1 antibodies in advancing biomedical research.